In a Nutshell
Semax is not FDA-approved in the US. Its real clinical history is Russian, in indications and a formulation that do not establish benefit for focus or cognition in otherwise healthy adults.
Semax is a synthetic peptide derived from ACTH (4–10), a fragment of adrenocorticotropic hormone, modified so that it does not carry the parent hormone's effects on cortisol. It is marketed for focus, cognition, mood and stress resilience.
Semax occupies an unusual position on this hub. Unlike most peptides here, it has a real clinical history — it has been used as a registered medicine in Russia for decades, including for stroke and cognitive indications, with a body of associated literature. That history is genuine and should not be dismissed.
It also does not transfer. That literature was largely generated outside the regulatory and methodological framework FDA applies, much of it is not readily accessible in English or indexed in the databases Western clinicians rely on, and it has not been independently replicated to the standard required for US approval. Semax is not an FDA-approved drug, and FDA's position is that it has "no, or limited, safety-related information for proposed routes of administration" 1.
On July 24, 2026 an FDA advisory committee voted 8–5 to recommend Semax for the 503A Bulks List — for cerebral ischemia, migraine and trigeminal neuralgia — contrary to the conclusions presented by FDA staff reviewers 2. FDA has not acted.
What Semax Is
ACTH is the pituitary hormone that instructs the adrenal glands to produce cortisol. A fragment of it — ACTH (4–10) — appears to carry effects on the nervous system separable from the hormonal ones. Semax is that fragment with a modification intended to slow its breakdown and extend activity.
The proposed mechanisms center on BDNF (brain-derived neurotrophic factor) and modulation of neurotransmitter systems. Research interest has focused on neuroprotection after ischemic injury rather than on cognitive enhancement in healthy people, which is how it is predominantly marketed.
That gap matters: a substance studied for recovery after stroke is not thereby established as beneficial for concentration in someone without neurological injury.
Current FDA and Compounding Status
Semax is not approved by FDA for any use.
It appears on FDA's list of bulk substances "nominated but withdrawn" — previously Category 2 1. The nominator later withdrew the nomination, but FDA elected to continue evaluating the free-base and acetate forms on its own initiative — which is why the substance still came before the committee. None of this is FDA clearance: removal from Category 2 does not by itself make a substance eligible for compounding.
Eligibility runs through one of three statutory routes under Section 503A — an applicable USP/NF monograph, being a component of an FDA-approved drug, or the 503A Bulks List — and every other 503A requirement still applies. For this substance FDA found no applicable USP/NF monograph and no FDA-approved drug containing it, so the 503A Bulks List is the only route identified in FDA's current review. The committee's vote did not add it to that list and changed no present authority to compound it.
FDA's stated concern: compounded Semax "may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities," with limited safety information for the proposed routes 1.
See the FDA peptide status page for the July votes in full.
On the Russian Clinical Literature
Because this comes up constantly, it is worth addressing directly rather than waving it away.
Semax has been used clinically in Russia since the 1990s, where the registered products are 0.1% and 1% nasal drops. There is published research, including clinical work in stroke and cognitive indications. Anyone claiming there is "no evidence at all" is overstating.
But that history is route- and product-specific, which changes what it can support. The human literature FDA identified used intranasal administration. FDA found no human safety literature for subcutaneous Semax, and frequently could not determine whether studies used Semax free base or a salt. The Russian intranasal record therefore cannot establish the safety of injectable or differently formulated compounded products — which is what is sold in the US.
Evidence generated outside the United States can inform clinical judgment, and discounting it for its origin would be poor reasoning. What limits these particular studies is specific and nameable: size, controls, blinding, reporting quality, independent replication, uncertain product identity and route, the population studied, and how closely the endpoints match the use being marketed. A foreign approval does not create an FDA approval — but the underlying evidence should be judged on its merits, not its nationality.
The honest position is therefore neither "proven" nor "no evidence," but: there is evidence, it has not been generated or replicated to the standard that would support a US clinical recommendation, and FDA has explicitly said it lacks adequate safety information.
What the Evidence Actually Shows
Evidence tier: C.
| Claim commonly made | What the evidence supports |
|---|---|
| Improves focus and concentration | Not established in controlled trials meeting US standards, particularly in healthy adults |
| Treats ADHD | Not an approved or evidence-based ADHD treatment |
| Neuroprotective after stroke | The strongest area of the Russian literature; not replicated to US standards |
| Improves mood / stress resilience | Preclinical and limited clinical data; not established |
Safety and What Is Unknown
- Human safety information is limited and route-specific. Intranasal exposure is reported in the Russian literature; the safety of subcutaneous compounded Semax has not been characterized 1
- Bleeding risk is an unresolved concern. FDA identified literature describing possible antithrombotic effects, raising a potential bleeding concern — particularly for anyone with a bleeding disorder or taking medicines that increase bleeding risk. This is not an established clinical rate, but anyone on an anticoagulant or antiplatelet should discuss Semax with their prescriber
- Long-term effects: unknown
- Psychiatric medicines: no clinically characterized interaction profile exists. Animal studies suggest effects on serotonergic and dopaminergic systems, but that does not establish an interaction with any specific medication in humans. Tell the clinician managing your medication — and do not stop or alter prescribed treatment on the strength of this page
- Not a substitute for evaluation: attention and cognitive difficulties have a long differential — sleep disorders, thyroid dysfunction, iron deficiency, depression, anxiety, perimenopause, ADHD. Several are treatable
- Pregnancy and breastfeeding: no data; not appropriate
- Product risk: most Semax in circulation is research-grade — see peptide sourcing and quality
Red Flags — Seek Care Now
- Sudden severe headache, weakness or numbness on one side, difficulty speaking, or vision loss — call 911. These are stroke symptoms and are not to be self-managed
- Difficulty breathing, facial or throat swelling, widespread hives — call 911
- Fever, spreading redness or swelling at an injection site
On Dosing
This page does not provide dosing protocols. No adequate dose-finding study has established a regimen for the product, route and use marketed in the US. If you are using Semax regardless, tell your clinician — particularly if you take any psychiatric medication.
What You Can Do About It
Regardless of suspected cause, thoughts of self-harm or a severe deterioration in mood need urgent help — call or text 988 in the US.
Brain fog, poor focus and low mood are common, real, and frequently traceable to something identifiable: sleep quality and undiagnosed sleep apnea; thyroid function; iron and B12; vitamin D; perimenopausal hormonal change; depression and anxiety; genuine ADHD, which has treatments with strong evidence. Each is assessable — see brain fog and fatigue.
Get Started with JumpstartMD
JumpstartMD was founded in 2007 by Stanford-trained physicians. Our programs are built around labs, hormones and body composition, delivered by licensed clinicians you see face-to-face — in person at 14 California locations or online across California — beginning with 60-biomarker lab screening and InBody® body composition scanning. InBody scans are done in clinic; online members can book one at any of the 14 locations.
Laboratory testing can identify some contributors — thyroid dysfunction, anemia, nutrient deficiencies, metabolic abnormalities. It does not diagnose ADHD, anxiety disorders, sleep apnea or most autoimmune conditions; those need clinical history, examination and, where indicated, targeted testing or referral.
Can you get semax on prescription?
Semax is not an FDA-approved drug, and FDA has not acted on the July 2026 advisory recommendation.
If the symptom or goal that led you here has not been evaluated, our clinicians can assess the relevant causes and evidence-based options — that assessment does not assume another peptide is the answer. Peptide care is offered through a paid membership, subject to clinical evaluation. Contact JumpstartMD for membership details and pricing.
Clinician-guided peptide therapy may be considered after an individualized clinical evaluation. Certain therapies may use compounded medications, which are not FDA-approved, and evidence, risks and expected outcomes vary by treatment. See peptide therapy.
Book FREE Consultation
Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.
Share your details and a JumpstartMD team member will reach out when we open.
Related Articles
- Are Peptides Legal in the US?
- How to Tell If a Peptide Is Legitimate
- Brain Fog — the treatable causes worth excluding first
- Peptide Therapy: What It Is and Who It's For
Frequently Asked Questions
What does Semax do to your body?
Semax is a modified fragment of ACTH proposed to act on BDNF and neurotransmitter signaling without the parent hormone's cortisol effects. Research interest has centered on neuroprotection after ischemic injury. What it does in healthy people taking it for focus has not been established in trials meeting US standards.
Is Semax used for ADHD?
Semax is not an approved or evidence-based treatment for ADHD in the US, and should not be used as one. ADHD has treatments with substantial evidence, and self-treating suspected ADHD with an unapproved peptide risks delaying an assessment that would lead to something that works.
Who should not take Semax?
No evidence-based contraindication list exists, because the required studies have not been done to US standards. On general principle it is not appropriate in pregnancy or breastfeeding, and anyone taking psychiatric medication should not add a substance proposed to modulate neurotransmitter systems without clinical oversight.
Is Semax stimulating?
Users describe varied subjective effects including alertness. These reports are anecdotal and uncontrolled — subjective stimulation is among the effects most susceptible to expectation, which is precisely why controlled trials exist.
Is Semax FDA approved?
No. An FDA advisory committee voted 8–5 in July 2026 to recommend it for the compounding bulks list for cerebral ischemia, migraine and trigeminal neuralgia, contrary to the conclusions presented by FDA staff reviewers. FDA has not acted, and compounding eligibility would not equal drug approval.
Semax is approved in Russia — doesn't that count for something?
It counts for something, but not enough to support a US clinical recommendation. The supporting literature was largely generated under different methodological and regulatory standards, is limited in independent replication, and is not fully accessible in English. FDA has stated separately that it lacks adequate safety information for the proposed routes.
References
- U.S. Food and Drug Administration, "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks." [Online]. Available: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks [Accessed: Jul. 25, 2026]. ↩
- Regulatory Affairs Professionals Society, "FDA advisory committee backs two more peptides, rejects one for compounding list," Jul. 2026. [Online]. Available: https://www.raps.org/resource/fda-advisory-committee-backs-two-more-peptides-rejects-one-for-compounding-list.html [Accessed: Jul. 25, 2026]. ↩
- The Hill, "FDA panel votes to add peptides to permitted compounding list despite opposition from agency scientists," Jul. 2026. [Online]. Available: https://thehill.com/homenews/5987510-fda-committee-votes-peptides/ [Accessed: Jul. 25, 2026]. ↩
- E. V. Medvedeva, V. G. Dmitrieva, O. V. Povarova, S. A. Limborska, V. I. Skvortsova, N. F. Myasoedov, L. V. Dergunova, "The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis," BMC Genomics, vol. 15, p. 228, Mar. 2014, [Online]. Available: https://doi.org/10.1186/1471-2164-15-228. PMID: 24661604. [Accessed: Jul. 25, 2026]. Preclinical (rat model). ↩